Pharmacokinetic profile and anthelmintic efficacy of moxidectin administered by different doses and routes to feedlot calves

2019 ◽  
Vol 266 ◽  
pp. 73-79 ◽  
Author(s):  
Luis Fazzio ◽  
Laura Moreno ◽  
Walter Galvan ◽  
Candela Canton ◽  
Luis Alvarez ◽  
...  
Keyword(s):  
Pharmacokinetic Profile ◽  
Anthelmintic Efficacy ◽  
Feedlot Calves ◽  
Different Doses

scholarly journals Comparative study of oxytetracycline and doxycycline on calcium chelation: in-vitro assay

2017 ◽  
Vol 6 (5) ◽  
pp. 1160 ◽  
Author(s):  
Savitri Katlam ◽  
Yeshwant A. Deshmukh ◽  
Pradeep R. Jadhav
Keyword(s):  
Absorption Spectrum ◽  
Calcium Binding ◽  
Binding Assay ◽  
Pharmacokinetic Profile ◽  
In Vitro Assay ◽  
Vitro Assay ◽  
Calcium Chelation ◽  
Different Doses ◽  
Uv Absorption Spectrum

Background: Tetracycline class of antibiotics differ in their pharmacokinetic profile and chelating property. Objective of present study is to assess the effect of oxytetracycline and doxycycline on calcium chelationMethods: For estimation of calcium chelation of Oxytetracycline and Doxycycline, EDTA method (P. Trinder) and calcium binding assay was followed. Different doses of Oxytetracycline (25 mg, 50 mg and 100 mg) and Doxycycline (25 mg, 50 mg and 100 mg) were used in EDTA method and different concentrations of calcium were used in calcium binding assay. The procedure was done according to the standard methodology.Results: The intensity of colour appear to be increased with increase in dose of the Oxytetracycline (25 mg, 50 mg, 100 mg) as the concentration of calcium binding increases. But in Doxycycline intensity of colour is more with 100 mg as compared with 25 mg and 50 mg The UV absorption spectrum of solution of Oxytetracycline (1mM) was changed after the addition of CaCl2 to provide different concentration of Ca2+ (0.1, 0.5 and 1.0 mM).  With minor shift in the absorption coefficient and no shift in wavelength were observed for Doxycycline.Conclusions: The study concludes that oxytetracycline has more calcium chelating property than doxycycline.

scholarly journals Anthelmintic Efficacy and Pharmacokinetics of Ivermectin Paste after Oral Administration in Mules Infected by Cyathostomins

Animals ◽  
2020 ◽  
Vol 10 (6) ◽  
pp. 934 ◽  
Author(s):  
Marilena Bazzano ◽  
Alessandra Di Salvo ◽  
Manuela Diaferia ◽  
Fabrizia Veronesi ◽  
Roberta Galarini ◽  
...  
Keyword(s):  
Body Weight ◽  
Serum Concentration ◽  
Area Under The Curve ◽  
Pharmacokinetic Profile ◽  
Post Treatment ◽  
Pharmacokinetic Parameters ◽  
Blood Samples ◽  
Off Label ◽  
Anthelmintic Efficacy ◽  
Mcmaster Method

Ivermectin (IVM) is an anthelmintic compound commonly used off-label in mules due to its broad-spectrum of activity. Despite the general use of IVM in mules with the same dose and route of administration licensed for horses, significant pharmacokinetic differences might exist between horses and mules, as already observed for donkeys. The aim of the present study was to evaluate the pharmacokinetic profile and anthelmintic efficacy of an oral paste of IVM in mules naturally infected with cyathostomins. Fifteen adult mules with fecal egg counts (FEC) ≥ 200 eggs per gram (EPG), with exclusive presence of cyathostomins, were included in the study. All mules were orally treated with IVM according to the manufacturer's recommended horse dosage (200 µg/kg body weight). FECs were performed before (day-10 and day-3) and after treatment at days 14 and 28 by using a modified McMaster method. The FEC reduction (FECR%) was also calculated. Blood samples were collected from five animals at various times between 0.5 h up to 30 days post treatment to determine pharmacokinetic parameters. The maximum IVM serum concentration (Cmax) was 42.31 ± 10.20 ng/mL and was achieved at 16.80 ± 9.96 h post-treatment (Tmax), area under the curve (AUC) was 135.56 ± 43.71 ng × day/mL. FECR% remained high (>95%) until the 28th day.

Meriones unguiculatus infected by Haemonchus contortus: evaluation of different experimental protocols

2018 ◽  
Vol 93 (04) ◽  
pp. 447-452
Author(s):  
L.T. Gressler ◽  
T.H. Grando ◽  
G. Machado do Carmo ◽  
R.A. Vaucher ◽  
L.M. Stefani ◽  
...  
Keyword(s):  
Haemonchus Contortus ◽  
Biochemical Parameters ◽  
Meriones Unguiculatus ◽  
Infective Larvae ◽  
The Third ◽  
Anthelmintic Efficacy ◽  
Experimental Protocols ◽  
Cell Alterations ◽  
Larval Burden ◽  
Different Doses

AbstractMany important studies on resistance reversion, anthelmintic efficacy and, especially, new molecules with antiparasitic effects are performed in laboratories using gerbils (Meriones unguiculatus) as the experimental model. This study aimed to evaluate the use of corticosteroids (dexamethasone and methylprednisolone acetate) in gerbils experimentally infected with different doses of infective larvae (sheathed or exsheathed) of Haemonchus contortus. In the first experiment, 28 gerbils were divided into seven groups infected by 2–6 × 103 larvae, with or without immunosuppression using corticosteroids. In the second experiment, eight gerbils were divided into two groups infected by 2 × 103 sheathed or exsheathed larvae. For the third assay, seven immunosuppressed gerbils were infected with 2 × 103 sheathed larvae and were killed 15 days post infection (PI). The highest number of parasites was recovered from methylprednisolone-immunosuppressed animals. We observed red and white blood cell alterations and biochemical parameters in infected animals that had undergone immunosuppression with methylprednisolone. We highlight that in the first and second experiments a satisfactory number of worms was recovered using sheathed larvae and immunocompetent animals. When exsheathed larvae were used, the number of worms recovered was unsatisfactory. A considerable larval burden was recovered from immunosuppressed gerbils 15 days PI, and body weight did not influence establishment of larvae.

Pharmacokinetic profile of dipyrone for different doses and multiple dosing

Pain ◽  
1987 ◽  
Vol 30 ◽  
pp. S47 ◽  
Author(s):  
M. Badian ◽  
D. Brockmeier ◽  
E. E. Dagrosa ◽  
H. G. Grigoleit ◽  
H. Grötsch ◽  
...  
Keyword(s):  
Pharmacokinetic Profile ◽  
Multiple Dosing ◽  
Different Doses

Pharmacokinetic profile, tissue residue depletion and anthelmintic efficacy of supramolecular fenbendazole

2021 ◽  
pp. 120957
Author(s):  
Anastasiya I. Varlamova ◽  
Pavel P. Kotchetkov ◽  
Ivan A. Arkhipov ◽  
Salavat S. Khalikov ◽  
Michael V. Arisov ◽  
...  
Keyword(s):  
Pharmacokinetic Profile ◽  
Tissue Residue ◽  
Anthelmintic Efficacy ◽  
Residue Depletion

No effect of vitamin D supplementation on metabolic parameters but on lipids in patients with type 2 diabetes and chronic kidney disease

2020 ◽  
pp. 1-10
Author(s):  
Jiwoon Kim ◽  
Ji Sun Nam ◽  
Heejung Kim ◽  
Hye Sun Lee ◽  
Jung Eun Lee
Keyword(s):  
Type 2 Diabetes ◽  
Chronic Kidney Disease ◽  
Vitamin D ◽  
Kidney Disease ◽  
Vitamin D Supplementation ◽  
Lipid Profiles ◽  
Metabolic Parameters ◽  
Injection Group ◽  
Different Doses

Abstract. Background/Aims: Trials on the effects of cholecalciferol supplementation in type 2 diabetes with chronic kidney disease patients were underexplored. Therefore, the aim of this study was to investigate the effects of two different doses of vitamin D supplementation on serum 25-hydroxyvitamin D [25(OH)D] concentrations and metabolic parameters in vitamin D-deficient Korean diabetes patients with chronic kidney disease. Methods: 92 patients completed this study: the placebo group (A, n = 33), the oral cholecalciferol 1,000 IU/day group (B, n = 34), or the single 200,000 IU injection group (C, n = 25, equivalent to 2,000 IU/day). 52% of the patients had less than 60 mL/min/1.73m2 of glomerular filtration rates. Laboratory test and pulse wave velocity were performed before and after supplementation. Results: After 12 weeks, serum 25(OH)D concentrations of the patients who received vitamin D supplementation were significantly increased (A, -2.4 ± 1.2 ng/mL vs. B, 10.7 ± 1.2 ng/mL vs. C, 14.6 ± 1.7 ng/mL; p < 0.001). In addition, the lipid profiles in the vitamin D injection group (C) showed a significant decrease in triglyceride and a rise in HDL cholesterol. However, the other parameters showed no differences. Conclusions: Our data indicated that two different doses and routes of vitamin D administration significantly and safely increased serum 25(OH)D concentrations in vitamin D-deficient diabetes patients with comorbid chronic kidney disease. In the group that received the higher vitamin D dose, the lipid profiles showed significant improvement, but there were no beneficial effects on other metabolic parameters.

Effects of Two Different Doses of Hirudin on APTT, Determined with Eight Different Reagents

1995 ◽  
Vol 73 (02) ◽  
pp. 219-222 ◽  
Author(s):  
Manuel Monreal ◽  
Luis Monreal ◽  
Rafael Ruiz de Gopegui ◽  
Yvonne Espada ◽  
Ana Maria Angles ◽  
...  
Keyword(s):  
Ex Vivo ◽  
Anticoagulant Activity ◽  
Subcutaneous Administration ◽  
In Vitro Study ◽  
Ex Vivo Model ◽  
Suitable Candidate ◽  
Significant Prolongation ◽  
High Doses ◽  
Different Doses

SummaryThe APTT has been considered the most suitable candidate to monitor the anticoagulant activity of hirudin. However, its use is hampered by problems of standardization, which make the results heavily dependent on the responsiveness of the reagent used. Our aim was to investigate if this different responsiveness of different reagents when added in vitro is to be confirmed in an ex vivo study.Two different doses of r-hirudin (CGP 39393), 0.3 mg/kg and 1 mg/kg, were administered subcutaneously to 20 New Zealand male rabbits, and the differences in prolongation of APTT 2 and 12 h later were compared, using 8 widely used commercial reagents. All groups exhibited a significant prolongation of APTT 2 h after sc administration of hirudin, both at low and high doses. But this prolongation persisted 12 h later only when the PTTa reagent (Boehringer Mannheim) was used. In general, hirudin prolonged the APTT most with the silica- based reagents.In a further study, we compared the same APTT reagents in an in vitro study in which normal pooled plasma was mixed with increasing amount of hirudin. We failed to confirm a higher sensitivity for silica- containing reagents. Thus, we conclude that subcutaneous administration of hirudin prolongs the APTT most with the silica-based reagents, but this effect is exclusive for the ex vivo model.

Dose Requirement for Replacement Therapy in Hemophilia A

1979 ◽  
Vol 42 (03) ◽  
pp. 825-831 ◽  
Author(s):  
Jean-Pierre Allain
Keyword(s):  
Clinical Effect ◽  
Hemophilia A ◽  
Clinical Results ◽  
Severe Hemophilia ◽  
Dose Requirement ◽  
Viii Level ◽  
The Relationship ◽  
In Vivo Recovery ◽  
Different Doses

SummaryIn order to determine the correlation between different doses of F. VIII and their clinical effect,. 70 children with severe hemophilia A were studied after treatment with single doses of cryoprecipitate. The relationship between plasma F. VIII levels or doses calculated in u/ kg of body weight and clinical results followed an exponential curve. Plasma F. VIII levels of 0.35 and 0.53 u/ml corresponded to 95 and 99% satisfactory treatment, respectively. Similar clinical results were obtained with 20 and 31 u/kg. When the in vivo recovery of F. VIII after lyophilized cryoprecipitate was 0.015 u/ml for each u/kg injected, plasma F. VIII levels of 0.30 and 0.47 u/ml respectively were achieved. Since home treatment is largely based on single infusions of F. VIII, it is suggested that moderate and severe hemorrhages be treated with a dose which will provide a plasma F. VIII level of 0.5 u/ml.

Clearance and In Vivo Release by Heparin of Human Platelet Factor 4 (PF4) in the Rabbit

1984 ◽  
Vol 52 (02) ◽  
pp. 157-159 ◽  
Author(s):  
M Prosdocimi ◽  
N Scattolo ◽  
A Zatta ◽  
F Fabris ◽  
F Stevanato ◽  
...  
Keyword(s):  
Half Life ◽  
Human Platelet ◽  
Slow Component ◽  
Platelet Factor 4 ◽  
Platelet Factor ◽  
In Vivo Release ◽  
Partial Release ◽  
Different Doses ◽  
New Zealand Rabbits

Summary13 male New Zealand rabbits were injected with two different doses (25 μg/Kg and 100 μg/Kg) of human platelet factor 4 antigen (PF4). The disappearance of the protein was extremely fast with an half-life for the fast component of 1.07 ± 0.16 and 1.76 ± 0.11 min respectively. The half-life for the slow component, detectable only with the highest dosage, was 18.8 min.The administration of 2500 I.U. of heparin 30 min after PF4 administration induced a partial release of the injected protein and its clearance from plasma was slow, with half-life of 23.3 ± 5.9 min and 30.9 ± 2.19 min respectively.

Significance of In-Vitro and In-Vivo Correlation in Drug Delivery System

2018 ◽  
Vol 4 (4) ◽  
pp. 523-531
Author(s):  
Hina Mumtaz ◽  
Muhammad Asim Farooq ◽  
Zainab Batool ◽  
Anam Ahsan ◽  
Ashikujaman Syed
Keyword(s):  
Dosage Form ◽  
Pharmaceutical Preparations ◽  
Pharmacokinetic Profile ◽  
In Vitro Dissolution ◽  
Time Saving ◽  
Pharmaceutical Dosage Form ◽  
Short Period ◽  
Form Development

The main purpose of development pharmaceutical dosage form is to find out the in vivo and in vitro behavior of dosage form. This challenge is overcome by implementation of in-vivo and in-vitro correlation. Application of this technique is economical and time saving in dosage form development. It shortens the period of development dosage form as well as improves product quality. IVIVC reduce the experimental study on human because IVIVC involves the in vivo relevant media utilization in vitro specifications. The key goal of IVIVC is to serve as alternate for in vivo bioavailability studies and serve as justification for bio waivers. IVIVC follows the specifications and relevant quality control parameters that lead to improvement in pharmaceutical dosage form development in short period of time. Recently in-vivo in-vitro correlation (IVIVC) has found application to predict the pharmacokinetic behaviour of pharmaceutical preparations. It has emerged as a reliable tool to find the mode of absorption of several dosage forms. It is used to correlate the in-vitro dissolution with in vivo pharmacokinetic profile. IVIVC made use to predict the bioavailability of the drug of particular dosage form. IVIVC is satisfactory for the therapeutic release profile specifications of the formulation. IVIVC model has capability to predict plasma drug concentration from in vitro dissolution media.

Sign in / Sign up

Export Citation Format

Share Document